Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial.
We performed a prospective, randomized, open-label equivalence study comparing the use of naproxen to aspirin in 33 patients with rheumatic fever. The mean time until resolution of arthritis was 2.9+/-2.9 days in both groups. Liver enzyme elevations were more frequent in the aspirin group (P=.002). We conclude that naproxen is as effective, is easier to use, and is safer than aspirin in the treatment of the arthritis of rheumatic fever.
D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001241:Aspirin / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D009288:Naproxen / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D011446:Prospective Studies; D012213:Rheumatic Fever / Q000188:drug therapy*; D013810:Therapeutic Equivalency; D013997:Time Factors; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D009288:Naproxen; D001241:Aspirin